NewAmsterdam Pharma
NewAmsterdam Pharma's revenue fell 50.6% to $22 million in fiscal 2025. Its operating margin was −1,002.9%, down from −386.9% a year earlier. Free cash flow was −$148 million. The diluted share count rose 25.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
NewAmsterdam Pharma lost money in fiscal 2025: a net loss of $204 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | — | 468 | 340 | 834 | 636 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −85.1x | −12.4x | — | — | — |
| Current ratio | — | 13.3x | 7.0x | 8.1x | 7.9x |
| Quick ratio | — | 13.3x | 7.0x | 8.1x | 7.9x |
Cash flow
Projections
Project NewAmsterdam Pharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $226,500 of NewAmsterdam Pharma shares on the open market, and 6 insiders sold $62.0 million, $43.4 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Michael H. DavidsonChief Executive Officer, Director | Bought | 10,000 | $22.65 | $226,500 | Form 4 |
| Sep 4, 2026 | John W SmitherDirector | Sold | 1,600 | $25.32 | $40,512 | Form 4 |
| Aug 24, 2026 | Johannes Jacob Pieter KasteleinChief Scientific Officer, Director | Sold plan | 125,000 | $26.91 | $3.4 million | Form 4 |
| Jul 20, 2026 | Louise Frederika KooijChief Accounting Officer | Sold plan | 105,000 | $30.34 | $3.2 million | Form 4 |
| Jun 22, 2026 | Louise Frederika KooijChief Accounting Officer | Sold plan | 40,000 | $30.20 | $1.2 million | Form 4 |
| May 26, 2026 | Louise Frederika KooijChief Accounting Officer | Sold plan | 65,000 | $35.69 | $2.3 million | Form 4 |
| Mar 11, 2026 | Louis G LangeDirector | Sold | 44,619 | $30.42 | $1.4 million | Form 4 |
| Mar 9, 2026 | Johannes Jacob Pieter KasteleinChief Scientific Officer, Director | Sold plan | 101,409 | $30.29 | $3.1 million | Form 4 |
| Mar 6, 2026 | Johannes Jacob Pieter KasteleinChief Scientific Officer, Director | Sold plan | 94,124 | $30.32 | $2.9 million | Form 4 |
| Mar 6, 2026 | Louis G LangeDirector | Sold | 28,186 | $29.41 | $828,950 | Form 4 |
| Mar 5, 2026 | Johannes Jacob Pieter KasteleinChief Scientific Officer, Director | Sold plan | 104,467 | $30.30 | $3.2 million | Form 4 |
| Mar 2, 2026 | Michael H. DavidsonChief Executive Officer, Director | Sold | 443,707 | $33.25 | $14.8 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −1,088.7% | −126.1% | −708.4% |
| Altman Z'' | 4.25 | 9.69 | 8.19 |
| Accruals ratio | −8.7% | −13.7% | −6.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | — | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Pass | Fail |
| F-score | — | — | — |
Compare
Put NewAmsterdam Pharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma | FY25 | −50.6% | −1,002.9% | −657.8% | — | — | — | |
| Alumis | FY25 | — | −1,886.9% | −1,539.2% | — | — | — | Compare |
| Scynexis | FY25 | 449.9% | −78.0% | — | — | — | 4 | Compare |
| Sol-Gel Technologies | FY25 | 68.0% | −38.9% | 1.4% | — | — | — | Compare |
| Celularity | FY25 | −51.0% | −230.9% | — | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | 103 | 14 | 46 | 22 |
| Revenue growth | — | — | — | −86.3% | 223.4% | −50.6% |
| Gross profit | — | — | — | — | — | — |
| Research and development | — | 29 | 87 | 159 | 151 | 142 |
| Operating income | — | −35 | −4 | −183 | −176 | −226 |
| Net income | — | −42 | −23 | −177 | −242 | −204 |
| Diluted EPS (US$) | — | −3.81 | −1.19 | −2.15 | −2.56 | −1.72 |
| Diluted shares (millions) | 4 | 11 | 19 | 82 | 94 | 118 |
| Cash flow | ||||||
| Cash from operations | — | −30 | 11 | −141 | −159 | −148 |
| Capital expenditure | — | 0 | 0 | 0 | 1 | 0 |
| Free cash flow | — | −30 | 10 | −141 | −159 | −148 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 1 | 4 | 25 | 34 | 59 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | — | — | 468 | 340 | 834 | 636 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | — | — | 478 | 347 | 865 | 769 |
| Total liabilities | — | — | 48 | 59 | 107 | 86 |
| Shareholders' equity | −73 | −114 | 430 | 288 | 758 | 683 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | −3.5% | −1,298.6% | −386.9% | −1,002.9% |
| Net margin | — | — | −22.0% | −1,255.8% | −530.2% | −905.7% |
| Free cash flow margin | — | — | 10.2% | −1,002.4% | −349.5% | −657.8% |
| Rule of 40 (growth + FCF margin) | — | — | — | −1,088.7% | −126.1% | −708.4% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | — | — | −49.2% | −46.2% | −28.3% |
| Return on assets | — | — | — | −42.9% | −39.9% | −24.9% |
| Net debt to EBITDA | — | — | — | — | — | — |